Global Psoriasis Pipeline Drugs Market 2018-2023: Cimzia (Certol - Tucson News Now

Global Psoriasis Pipeline Drugs Market 2018-2023: Cimzia (Certolizumab Pegol), Tildrakizumab (MK-3222), Risankizumab (BI 655066), FP187, Skilarence (LAS41008) & Duobrii (IDB 118)

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE Research and Markets

DUBLIN, March 5, 2018 /PRNewswire/ --

The "Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" report has been added to's offering.

Research and Markets Logo

The global psoriasis drugs market is projected to display a robust growth during 2019-2023, chiefly driven by low efficacy and tolerability of present psoriasis drugs and improved safety and efficacy of investigational drugs.

The report presents the market potential of six major pipeline drugs meant for the treatment of Psoriasis. These six drugs that fall in the various categories of Injectables, Oral pills and Topical creams/lotions by mode of administration have been recognized as being clinically effective in Psoriasis treatment. Expected to be launched in the market within the next 4-5 years, these six potential drugs are likely to bring about major changes in the way psoriasis is treated globally.

Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.

Over the recent years, the Psoriasis Drugs market is growing rapidly due to rising prevalence of Psoriasis patients around the world. Globally, the growth of Psoriasis Drugs market is driven by rising psoriatic population.

The report has covered and analysed the major psoriasis drugs that are in pipeline and expected to be launched in the near future. The product profile, assessment of clinical trials, the regulatory phases and the potential of the drugs has been analysed in the report. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decision.

Key Topics Covered:

1. Research Methodology

2. Psoriasis - An Overview

2.1. Symptoms of Psoriasis

2.2. Types of Psoriasis

2.3. Causes of Psoriasis

2.4. Triggers, Risk Factors and Complications of Psoriasis

3. Diagnosis of Psoriasis

4. Treatment of Psoriasis

5. Anti-Psoriasis Pipeline Drugs

5.1. Anti-Psoriasis Pipeline Drugs - Cimzia (Certolizumab Pegol)

5.2. Anti-Psoriasis Pipeline Drugs - Tildrakizumab (MK-3222)

5.3. Anti-Psoriasis Pipeline Drugs - Risankizumab (BI 655066)

5.4. Anti-Psoriasis Pipeline Drugs - FP187

5.5. Anti-Psoriasis Pipeline Drugs - Skilarence (LAS41008)

5.6. Anti-Psoriasis Pipeline Drugs - Duobrii (IDB 118)

6. Company Profiles

6.1. UCB

6.2. Sun Pharmaceutical Industries Ltd

6.3. Boehringer Ingelheim

6.4. Forward Pharma

6.5. Almirall

6.6. Valeant Pharmaceuticals

7. Number of Psoriasis Patients By Country

7.1. U.S

7.2. U.K

7.3. France

7.4. Italy

7.5. Germany

7.6. Norway

Companies Featured

  • UCB
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim
  • Forward Pharma
  • Almirall
  • Valeant Pharmaceuticals

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Cision View original content:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly